Mu-opioid receptor heterooligomer formation with the dopamine D1 receptor as directly visualized in living cells

European Journal of Pharmacology

Volumn 581, Issue 3, 2008, Pages 235-243

  Juhasz, Jason R ^a   Hasbi, Ahmed ^a   Rashid, Asim J ^a   So, Christopher H ^a   George, Susan R ^a,b   O'Dowd, Brian F ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Cell surface expression; Dopamine D1 receptors; Hetero oligomerization; Mu opioid receptors; Nuclear localization signal

Indexed keywords

DOPAMINE 1 RECEPTOR; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; MU OPIATE RECEPTOR; OLIGOMER;

ARTICLE; BINDING AFFINITY; BRAIN NERVE CELL; CAUDATE NUCLEUS; CELL MEMBRANE PERMEABILITY; CELL SURFACE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN TRANSPORT;

CELL LINE; CELL NUCLEUS; HUMANS; KIDNEY; PROTEIN TRANSPORT; RECEPTORS, DOPAMINE D1; RECEPTORS, OPIOID, MU;

EID: 38949100387     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.11.060     Document Type: Article

References (22)

1. Andersson H., D'Antona E., Kendall D.A., Von Heijne G., and Chin Cl. Membrane assembly of the cannabinoid receptor 1: impact of a long N-terminal tail. Mol. Pharmacol. 64 (2003) 570-577
2. Angers S., Salahpour A., and Bouvier M. Biochemical and biophysical demonstration of GPCR oligomerization in mammalian cells. Life Sci. 68 (2001) 2243-2250
3. Arvidsson U., Riedl M., Chakrabarti S., Lee J.H., Nakano A.H., Dado R.J., Loh H.H., Law P.Y., Wessendorf M.W., and Elde R. Distribution and targeting of a mu-opioid receptor (MOR1) in brain and spinal cord. J. Neurosci. 15 (1995) 3328-3341
4. 1 receptor deficient mice. Naunyn-Schmiedeberg's Arch. Pharmacol. 363 (2001) 562-568
5. 1 receptor by a new membrane-associated ER protein. Nat. Cell Biol. 3 (2001) 492-498
6. Fan T., Varghese G., Nguyen T., Tse R., O'Dowd B., and George S.R. A role for the distal carboxyl tails in generating the novel pharmacology and G protein activation profile of mu and delta opioid receptor hetero-oligomers. J. Biol. Chem. 280 (2005) 38478-38488
7. George S.R., Fan T., Xie Z., Tse R., Tam V., Varghese G., and O'Dowd B.F. Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties. J. Biol. Chem. 275 (2000) 26128-26135
8. Hasbi A., Devost D., Laporte S.A., and Zingg H.H. Real-time detection of interactions between the human oxytocin receptor and G protein-coupled receptor kinase-2. Mol. Endocrinol. 18 (2004) 1277-1286
9. Herrick-Davis K., Grinde E., and Mazurkiewicz J.E. Biochemical and biophysical characterization of serotonin 5-HT2C receptor homodimers on the plasma membrane of living cells. Biochemistry 43 (2004) 13963-13971
10. Hnasko T.S., Sotak B., and Palmiter R. Morphine reward in dopamine-deficient mice. Nature 438 (2005) 854-857
11. Jans D.A., Xiao C.Y., and Lam M.H. Nuclear targeting signal recognition: a key control point in nuclear transport?. Bioessays 22 (2000) 532-544
12. Leclerc P.C., Auger-Messier M., Lanctot P., Escher E., Leduc R., and Guillemettw G. A polyaromatic caveolin-binding-like motif in the cytoplasmic tail of the type 1 receptor for angiotensin II plays an important role in receptor trafficking and signaling. Endocrinology 143 (2002) 4702-4710
13. 2 dopamine receptor homodimerization is mediated by multiple sites of interaction including an intermolecular interaction involving transmembrane domain 4. Biochemistry 42 (2003) 11023-11031
14. 2 receptor co-activation generates a novel phospholipase C-mediated calcium signal. J. Biol. Chem. 279 (2004) 35671-35678
15. Margeta-Mitrovic M., Jan Y., and Jan L. Function of GB1 and GB2 subunits in G protein coupling of GABA(B) receptors. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 14649-14654
16. Milligan G., Ramsay D., Pascal G., and Carrillo J.J. GPCR dimerisation. Life Sci. 74 (2003) 181-188
17. O'Dowd B.F., Ji X., Alijaniaram M., Rajaram R., Kong M., Rashid A., Nguyen T., and George S.R. Dopamine receptor oligomerization visualized in living cells. J. Biol. Chem. 280 (2005) 37225-37235
18. O'Dowd B.F., Alijaniaram M., Ji X., Nguyen T., Eglen R.M., and George S.R. Using ligand-induced conformational change to screen for compounds targeting G-protein-coupled receptors. J. Biomol. Screen. 12 (2007) 175-185
19. Pak Y., Kouvelas A., Scheidler M., Rasmussen J., O'Dowd B.F., and George S.R. Agonist-induced functional desensitization of the mu-opioid receptor is mediated by loss of membrane receptors rather than uncoupling from G protein. Mol. Pharmacol. 50 (1996) 1214-1222
20. 2 dopamine receptors form heterooligomers and cointernalize after selective activation of either receptor. Mol. Pharmacol. 68 (2005) 568-578
21. 1 receptor chimeras reveal modulation of partial agonist activity by carboxyl-terminal tail sequences. J. Neurochem. 71 (1998) 2593-2599
22. Zarrindast M.R., Azami B., Rostami P., and Rezayof A. Repeated administration of dopaminergic agents in the nucleus accumbens and morphine-induced place preference. Behav. Brain Res. 169 (2006) 248-255